Short interest for Avadel Pharmaceuticals gives investors a sense of the degree to which investors are betting on the decline of Avadel Pharmaceuticals's stock. Short interest data is updated every two weeks.

Avadel Pharmaceuticals Stock (NASDAQ:AVDL), Short Interest Report

Avadel Pharmaceuticals

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.

News

Price Target

Small Cap

Markets

Analyst Ratings

Trading Ideas

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

VEEV

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

American Airlines To Rally Around 42%? Here Are 10 Top Analyst Forecasts For Tuesday

Earnings

Avadel Pharmaceuticals plc  (NASDAQ: AVDL) reported better-than-expected fourth-quarter revenue results and also issued a corporate update on Monday.

Avadel Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results

Long Ideas

Insider Trades

Pre-Market Outlook

KALV

Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.

Insiders Buying Dorian LPG And 2 Other Stocks

Avadel Pharmaceuticals plc - Ordinary Share

Avadel Pharmaceuticals PLC

Lockheed-Boeing Alliance Faces U.S. Penalties For Launch Delay; Air Force Cites 'Schedule Slip,' Withholds Fee Details

Filecoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/fil/usd">FIL</a>) price has decreased 3.46% over the past 24 hours to $5.38, continuing its downward trend over the past week of -9.0%, moving from $5.91 to its current price. 
The chart below compares the price movement and volatility for Filecoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715713422_0.png" alt="price_chart" />
The trading volume for the coin has decreased 17.0% over the past week, while the overall circulating supply of the coin has increased 0.53% to over 551.58 million. This puts its current circulating supply at an estimated 28.13% of its max supply, which is 1.96 billion. The current market cap ranking for FIL is #39 at $2.97 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715713422_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$FIL

Cryptocurrency Filecoin Decreases More Than 3% Within 24 hours

The Industrial Products group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ABB (OTC: <a class="ticker" href="https://www.benzinga.com/stock/abbny#OTC">ABBNY</a>) one of those stocks right now? Let&#39;s take a closer look at the stock&#39;s year-to-date performance to find out.
ABB is one of 222 companies in the Industrial Products group. The Industrial Products group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ABB is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ABBNY&#39;s full-year earnings has moved 0.5% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that ABBNY has returned about 18.5% since the start of the calendar year. Meanwhile, stocks in the Industrial Products group have gained about 9.3% on average. This shows that ABB is outperforming its peers so far this year.
Bodycote (OTC: <a class="ticker" href="https://www.benzinga.com/stock/byplf#OTC">BYPLF</a>)&nbsp;is another Industrial Products stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 13.6%.
For Bodycote, the consensus EPS estimate for the current year has increased 0.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ABB is a member of the Manufacturing - Electronics industry, which includes 16 individual companies and currently sits at #80 in the Zacks Industry Rank. Stocks in this group have gained about 19.9% so far this year, so ABBNY is slightly underperforming its industry this group in terms of year-to-date returns.
Bodycote, however, belongs to the Manufacturing - Thermal Products industry. Currently, this 4-stock industry is ranked #15. The industry has moved +12.3% so far this year.
Investors with an interest in Industrial Products stocks should continue to track ABB and Bodycote. These stocks will be looking to continue their solid performance.
<a href="https://www.zacks.com/stock/news/2273484/are-industrial-products-stocks-lagging-abb-abbny-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-2273484">To read this article on Zacks.com click here.</a>

ABBNY

BYPLF

Are Industrial Products Stocks Lagging ABB This Year?

Mantle's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MNT</a>) price has decreased 3.48% over the past 24 hours to $0.96, continuing its downward trend over the past week of -10.0%, moving from $1.06 to its current price. 
The chart below compares the price movement and volatility for Mantle over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715713353_0.png" alt="price_chart" />
The trading volume for the coin has decreased 29.0% over the past week, while the overall circulating supply of the coin has increased 0.11% to over 3.26 billion. This puts its current circulating supply at an estimated 52.49% of its max supply, which is 6.22 billion. The current market cap ranking for MNT is #36 at $3.13 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715713353_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$MNT

Cryptocurrency Mantle Decreases More Than 3% Within 24 hours

Over the past 24 hours, Immutable's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">IMX</a>) price has fallen 7.64% to $2.06. This continues its negative trend over the past week where it has experienced a 7.0% loss, moving from $2.21 to its current price. 
The chart below compares the price movement and volatility for Immutable over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715713344_0.png" alt="price_chart" />
The trading volume for the coin has increased 16.0% over the past week while the overall circulating supply of the coin has increased 0.06% to over 1.46 billion which makes up an estimated 72.84% of its max supply, which is 2.00 billion. The current market cap ranking for IMX is #37 at $3.00 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715713344_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$IMX

Cryptocurrency Immutable Down More Than 7% Within 24 hours

NiSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NI#NYSE">NI</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $30.75, a high estimate of $32.00, and a low estimate of $29.00. This current average reflects an increase of 4.24% from the previous average price target of $29.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1715713302_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of NiSource by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$29.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to NiSource. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NiSource compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of NiSource's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of NiSource's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NiSource analyst ratings.</a>
<h2>About NiSource</h2>
NiSource is one of the nation's largest natural gas distribution companies with approximately 3.2 million customers in Indiana, Kentucky, Maryland, Ohio, Pennsylvania, and Virginia. NiSource's electric utility transmits and distributes electricity in northern Indiana to about 500,000 customers. The regulated electric utility also owns more than 3,000 megawatts of generation capacity, including coal, natural gas, and renewable energy.
<h3>NiSource's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: NiSource's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -13.21%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Utilities sector.
Net Margin: NiSource's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.16% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): NiSource's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.39%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): NiSource's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.14%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.64.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For NiSource

Total Wine &amp; More, often called &#8220;America's Wine Superstore&#8221; as it is the largest independent retailer of fine wine in the U.S., has been at it since 1991 when brothers David and Robert Trone opened a small shop in Delaware. They now operate more than 260 superstores across 28 states. The company in a cool $6 billion in revenue in 2023.
And now, it&#8217;s featuring a special drink for its millions of customers to try: cannabis beverages.
What Happened: Total Wine &amp; More is partnering with Bayou City Hemp Company and 88th Wonder and will add their full portfolio of hemp-derived THC beverages to all of its 38 wine stores throughout Texas and all five Louisiana locations. Products available include HOWDY, Beach Break and 8th Wonder Cannabis.
<h2 class="wp-block-heading">Win-Win And Win For All Involved &#8211; And That Includes Consumers</h2>
"Our THC beverages are taking Texas by storm and this partnership with Total Wine &amp; More is a major advancement in our mission to bring these products to the mainstream," said Ben Meggs, CEO of Bayou City Hemp and 8th Wonder. "These non-alcoholic beverages are widely sought after and we're thrilled to make them accessible to the customers of such an iconic and reputable company in the Lone Star State and Louisiana. In a short amount of time, our products have emerged as some of the top sellers in Texas Total Wines."
Bayou City Hemp acquired 8th Wonder, Houston's decade-old brewery and distillery, in 2023 to become a vertically integrated cannabis and craft beverage company. The high-quality product and science-based processes for extracting THC from hemp have made the company the gold standard for cannabis products across Texas and beyond.
Total Wine's groundbreaking move to introduce hemp-derived THC beverages to its customers provides a level of legitimacy to this new and emerging industry. This combined with Total Wine &amp; More's already well-known values and consumer confidence makes it the ideal partner for this huge step forward in the THC beverage category. 
<h2 class="wp-block-heading">Expansion Throughout Texas</h2>
Restaurants, music venues, movie theaters, bars and even family-friendly bowling alleys have embraced cannabis, proving that hemp-derived THC beverages are quickly becoming the new normal. Over 1000 major metro retailers in the Lone Star State have embraced these products with open arms thanks in large part to earned consumer trust. Bayou City Hemp and 8th Wonder expect to see their footprint double over the next month as other retailers add the full portfolio to their shelves, menus, and bars. &nbsp;&nbsp;
<h2 class="wp-block-heading">Nationwide Appeal</h2>
With placement secured in every major metro area across the state, the teams at Bayou City Hemp and 8th Wonder have begun to set their sights on expansion into new territories.
"Our portfolio of THC-infused beverages continues to expand due to the overwhelming popularity of our products," said Meggs. "Consumer trends have shaped the future of our brand and business. We adapt to meet the preferences of our consumers, which is why we are leaning into these alcohol alternatives and we're seeing massive success."
Courtesy photo

Cannabis Beverages At Liquor Stores? Largest Wine Retailer In US, Selling $6B/Year, Adding THC To The Menu

Aptos's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">APT</a>) price has decreased 4.79% over the past 24 hours to $7.88, continuing its downward trend over the past week of -12.0%, moving from $8.94 to its current price. 
The chart below compares the price movement and volatility for Aptos over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715713274_0.png" alt="price_chart" />
The trading volume for the coin has increased 6.0% over the past week while the overall circulating supply of the coin has increased 1.33% to over 433.96 million. The current market cap ranking for APT is #32 at $3.42 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715713274_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$APT

Cryptocurrency Aptos Falls More Than 4% In 24 hours

During the last three months, 5 analysts shared their evaluations of Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $30.6, a high estimate of $40.00, and a low estimate of $8.00. Observing a 27.5% increase, the current average has risen from the previous average price target of $24.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1715713257_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Capricor Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aydin Huseynov</td>
<td>Ladenburg Thalmann</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Capricor Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Capricor Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Capricor Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Capricor Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Capricor Therapeutics</h2>
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
<h3>Unraveling the Financial Story of Capricor Therapeutics</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Capricor Therapeutics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 1159.3%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -6.3%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Capricor Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.32% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.59%, the company showcases effective utilization of assets.
Debt Management: Capricor Therapeutics's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAPR

Expert Ratings For Capricor Therapeutics

6 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.5, a high estimate of $22.00, and a low estimate of $13.00. A decline of 6.67% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1715713239_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Amicus Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Karl Chalabala</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$22.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Amicus Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Amicus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Amicus Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Amicus Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FOLD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amicus Therapeutics analyst ratings.</a>
<h2>Unveiling the Story Behind Amicus Therapeutics</h2>
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
<h3>Unraveling the Financial Story of Amicus Therapeutics</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Amicus Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 27.97% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amicus Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -43.86% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amicus Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -33.29%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Amicus Therapeutics's ROA excels beyond industry benchmarks, reaching -6.46%. This signifies efficient management of assets and strong financial health.
Debt Management: Amicus Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.4, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FOLD

Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has outperformed the market over the past 20 years by 8.53% on an annualized basis producing an average annual return of 16.65%. Currently, Humana has a market capitalization of $40.39 billion. 
Buying $100 In HUM: If an investor had bought $100 of HUM stock 20 years ago, it would be worth $2,183.35 today based on a price of $335.18 for HUM at the time of writing.
<h3>Humana's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715713234_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,200 Today

Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) has outperformed the market over the past 15 years by 4.48% on an annualized basis producing an average annual return of 16.88%. Currently, Texas Instruments has a market capitalization of $173.96 billion. 
Buying $100 In TXN: If an investor had bought $100 of TXN stock 15 years ago, it would be worth $1,056.75 today based on a price of $191.06 for TXN at the time of writing.
<h3>Texas Instruments's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715713228_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Texas Instruments 15 Years Ago Would Be Worth This Much Today

Alphabet Inc.'s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)&nbsp;Google&nbsp;today made several announcements around Gemini and its upcoming AI-powered features at its annual I/O developer conference.
What Happened: A year after announcing Gemini, Sundar Pichai-led tech giant revealed that over one and half million developers are using Gemini to build and debug code, get insights and build AI applications
AI Overviews:&nbsp;AI Overviews, a revamped version of Search Generative Experiences will be launched starting today in the United States. AI Overviews has specifically been designed for complex questions that may require multi-step reasoning.
This can be used to perform several tasks such as creating diet plans, organizing trips&nbsp;and&nbsp;more.
AI Overviews will also enable you to use videos to ask questions, be it for troubleshooting something or learning about something&nbsp;that is&nbsp;in front of you.
See Also:<a target="_blank" href="https://www.benzinga.com/news/24/05/38808197/despite-microsofts-13b-funding-openai-snubs-top-investor-launches-chatgpt-app-for-apple-macs-ahead-o" rel="noreferrer noopener">&nbsp;Despite&nbsp;Microsoft&#8217;s&nbsp;$13B Funding, OpenAI Snubs Top Investor: Launches ChatGPT App For Apple Macs Ahead Of&nbsp;Windows</a>
Google Photos:&nbsp;Google Photos is getting a new feature, Ask Photos. The Ask Photos feature will allow users to enter a question such as&nbsp;"What's my license plate&nbsp;number"&nbsp;and&nbsp;Google Photos will search in your photos and library and share the answer&nbsp;with you.
Google claimed that six billion photos and videos each day are uploaded on Google Photos each day. Gemini can even create summaries and create a package containing photos and videos.
Ask Photos will be rolled out this summer, with more features&nbsp;being added&nbsp;later.
Google Workspace:&nbsp;Gemini&nbsp;will now be able to&nbsp;summarize your emails and create highlights from meetings recorded on Google Meet.&nbsp;It will also allow you&nbsp;to quickly draft&nbsp;replies for emails&nbsp;using a prompt.
Subscribe to the<a target="_blank" href="https://bztechtrends.beehiiv.com/subscribe" rel="noreferrer noopener">&nbsp;Benzinga Tech Trends newsletter</a>&nbsp;to&nbsp;get&nbsp;all the latest tech developments&nbsp;delivered&nbsp;to your inbox.
Audio Overview:&nbsp;NotebookLM has received a new feature, Audio Overview, which allows you to use files to create a personalized audio guide using the inputs. The Audio Overview feature will also&nbsp;allow&nbsp;the users to pause the guide and ask the AI questions&nbsp;to better understand the topic.
AI Agents:&nbsp;Google also revealed that it is working on making AI more helpful for users. Users&nbsp;will be able to&nbsp;plan their travel, find receipts, search for their phone&nbsp;and&nbsp;even arrange product returns easily.
New Gemini Models:&nbsp;Gemini 1.5 Pro and Flash are now accessible worldwide, spanning&nbsp;more than&nbsp;200 countries and territories. The pricing&nbsp;is established&nbsp;at $7 for Gemini 1.5 Pro, $3.50 for a maximum of 128K tokens, and Flash&nbsp;is offered&nbsp;at $0.35 for 1 million tokens. Gemini 1.5 Flash is a lightweight model when compared to Gemini Pro. It has&nbsp;been designed&nbsp;to be cost-efficient and fast.
Project Astra:&nbsp;Google DeepMind CEO Demis Hassabis announced Project Astra, a universal AI agent for everyday life. Hassabis claims this is why Gemini will be multimodal as it will enable it to be naturally conversational. According to him, the conversations will feel more natural with Astra.
Music AI Sandbox:&nbsp;Google has also announced a generative music model, the Music AI Sandbox, which has reportedly been developed with songwriters, musicians&nbsp;and&nbsp;producers.
Veo:&nbsp;After generative music, Google has announced Veo, a generative video model, that can create Full HD videos in different cinematic styles using text, image&nbsp;and&nbsp;video prompts. You can also use Veo to further edit the videos using additional prompts. Veo can be used in VideoFX, allowing creators and editors a new way of making videos.
Trillium:&nbsp;Google announced its sixth-gen Tensor Processing Unit (TPU), Trillium, which Pichai said is 4.6 times better than its predecessor. It will be available to cloud customers starting in late 2024.
Google for Workspaces:&nbsp;Side Panel will be available for Google for Workspaces next month. The Gemini-powered Side Panel comes with features such as "help me write" and "help me visualize".
Gemini will also be integrated with Google Meet and is being expanded to 68 languages.
Gmail Mobile:&nbsp;Gmail mobile is getting three new features, which include a summarize button that creates a mobile card from long texts, a Q&amp;A feature to get quick answers using your inbox&nbsp;and&nbsp;suggested replies, which are based on existing email threads.
AI Teammate:&nbsp;An&nbsp;AI Teammate is a Gemini-powered teammate who can be assigned a specific role or a job to make it efficient for the company. It can be assigned to monitor projects and answer questions based on these inputs.
Gems:&nbsp;Users can create "Gems" on the Gemini app. Gems are personal experts that can be created on Gemini to perform actions tailored to whatever you need. Gems will be rolled out in the coming months.
AI Fraud Detection:&nbsp;Google is also working on a new call monitoring feature that will help prevent fraud. This feature will warn a person if the person they are talking to is attempting to fraud them. It will warn users about potential scams and advise them against sending money to unknown callers.
Check out more of Benzinga&#8217;s Consumer Tech coverage by<a href="https://www.benzinga.com/topic/consumer-tech"> following this link</a>.
Read Next:<a href="https://www.benzinga.com/news/24/05/38695318/from-beginner-to-enthusiast-top-5-free-harvard-courses-to-spark-your-ai-journey-with-machine-learnin?itm_source=parsely-api"> From Beginner To Enthusiast: Top 5 Free Harvard Courses To Spark Your AI Journey With Machine Learning</a>
Photo courtesy: Google

Tech

GOOG

GOOGL

At Google I/O 2024, Sundar Pichai And Team Announce New Gemini Models, Project Astra, AI Fraud Protection And More: Here's All You Need To Know

Ethereum Classic's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/etc/usd">ETC</a>) price has decreased 3.51% over the past 24 hours to $25.41, continuing its downward trend over the past week of -8.0%, moving from $27.74 to its current price. 
The chart below compares the price movement and volatility for Ethereum Classic over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1715713204_0.png" alt="price_chart" />
The trading volume for the coin has increased 6.0% over the past week while the overall circulating supply of the coin has increased 0.69% to over 147.05 million which makes up an estimated 69.79% of its max supply, which is 210.70 million. The current market cap ranking for ETC is #31 at $3.74 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1715713204_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$ETC

Cryptocurrency Ethereum Classic Down More Than 3% Within 24 hours

<a href="https://www.statnews.com/pharmalot/2024/05/14/amgen-lumakras-durbin/" title="https://www.statnews.com/pharmalot/2024/05/14/amgen-lumakras-durbin/">https://www.statnews.com/pharmalot/2024/05/14/amgen-lumakras-durbin/</a>

Legal

AMGN

'Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug' -STAT News

Anglo American (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AAUKF#OTCQX">AAUKF</a>) plans to sell some of its legacy assets, notably its diamond business, De Beers, South Africa-based Anglo American Platinum, and <a href="https://widgets.benzinga.com/topic/coal">steelmaking coal assets</a>.
The sale process is part of Anglo American&#8217;s strategy to safeguard itself against the <a href="https://www.benzinga.com/news/large-cap/24/05/38816720/anglo-american-rejects-bhps-improved-bid-rio-tinto-remains-contender-for-prized-copper-assets">persistent takeover attempts</a> by mining giant BHP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>).
"These actions represent the most radical changes to Anglo American in decades," CEO Duncan Wanblad <a href="https://www.angloamerican.com/media/press-releases/2024/14-05-2024">said</a>, clarifying that BHP&#8217;s intensified takeover offers accelerated the pre-planned action review of assets.
Wanblad described the company&#8217;s restructuring plan as clear, compelling, and decisive, aimed at unlocking significant shareholder value by focusing on world-class assets, particularly in the copper sector. 
He expressed confidence that Anglo American would reach exceptional valuation levels by the end of 2025.
See Also: <a href="https://www.benzinga.com/news/24/05/38791907/australia-injects-374m-into-critical-minerals-exploration-weve-got-some-huge-advantages">Australia Injects $374M Into Critical Minerals Exploration: &#8216;We&#8217;ve Got Some Huge Advantages&#8217;</a>
Why It Matters: This sale allows for a sharpened focus on copper, iron ore, and crop nutrients. Wanblad anticipates these sectors will experience significant value appreciation by the end of 2025. 
<a href="https://www.benzinga.com/topic/copper">Copper</a>, in particular, is witnessing a surge in demand due to its critical role in the green energy transition, serving as a core material for electric vehicles and renewable energy infrastructure.
In addition to the asset divestment, Anglo American is eyeing strategic partnerships for its Woodsmith fertilizer project in northeast England. Wanblad emphasized the need for investors to support the project&#8217;s full-scale operations, slated to commence in 2026.
While BHP still has one whole week to review its offer, the complexities regarding the transaction still loom. Most recently, South Africa's mineral minister, Gwede Mantashe, expressed reservation regarding BHP's offer but clarified it as a personal opinion rather than an official sentiment.
Price Action: Anglo American is currently trading $16.47 a share, down 2.87% at last check Tuesday. 
Shares rallied late in the London season, closing 1.4% in the green on the day. Meanwhile, BHP closed the day 0.23% in the red, and its year-to-date decline now stands at 14.6%.
Benzinga Mining is the bridge between mining companies and retail investors. Reach out to <a href="mailto:licensing@benzinga.com">licensing@benzinga.com</a> to get started!
Now Read:<a href="https://www.benzinga.com/news/large-cap/24/05/38760388/new-mining-alliance-targets-copper-exploration-in-arizona-new-mexico-and-utah"> New Mining Alliance Targets Copper Exploration In Arizona, New Mexico, And Utah</a>
Image: Shutterstock

Large Cap

Commodities

AAUKF

Anglo American Expedites Plan To Divest De Beers, Other Assets After Rebuffing BHP Takeover Bid

Needham&nbsp;analyst Quinn Bolton reiterated&nbsp;D-Wave&nbsp;Quantum Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) with a Buy rating and a&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/QBTS/analyst-ratings" rel="noreferrer noopener">$2.50&nbsp;price target</a>.
Bolton noted that D-Wave reported&nbsp;total revenues of $2.5 million&nbsp;in the quarter, below consensus expectations of $3.0 million. The $2.465 million top-line number represented an&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38784340/d-wave-reports-first-quarter-2024-results" rel="noreferrer noopener">increase of 55.7% on an annualized basis.</a>
Management reported bookings of $4.5 million, which represented a 54% year-over-year increase relative to 2023.&nbsp;
For the second quarter, management&nbsp;did not provide a target for bookings and revenue following a significant increase in bookings in the first quarter. Regarding strategy, the company wants to expand its commercial customer base further,&nbsp;comprising ~70% of all revenues on a trailing 12-month basis.
Bolton flagged that quarterly bookings increased year over year for the eighth consecutive quarter, were broad-based, and included two large multi-year orders.&nbsp;
He also highlighted that D-Wave introduced its new fast anneal feature,&nbsp;which significantly accelerates&nbsp;quantum processing speeds. Since its launch in April, more than 530k jobs have taken advantage of fast anneal.
He noted that the technology roadmap continues&nbsp;to progress, as the company recently yielded 4,800+ qubit processors for its upcoming Advantage2 system.&nbsp;&nbsp;
D-Wave renewed its multi-year partnership with USC, Bolton added. Bolton projected second-quarter revenue and EPS of $2.8 million and $(0.08).
Benchmark&nbsp;analyst David Williams maintained a Buy rating on D-Wave Quantum with a price target of $4.
Williams said that D-Wave&#8217;s first-quarter bookings show continued momentum. They benefit from the recent demonstration of potentially achieving Quantum Supremacy,&nbsp;which is&nbsp;driving&nbsp;strong inbound&nbsp;interest.&nbsp; &nbsp;
While QBTS continues to drive commercial momentum, the analyst is encouraged by the expansion of funding opportunities in the recent National Defense Authorization Act, which now includes language to support annealing, hybrid approaches, and gate models.&nbsp;&nbsp;
He noted these government-supported quantum computing initiatives will generate meaningful new opportunities for D-Wave to participate in hardware sales, adding another revenue stream to the current commercially driven QCaaS and services revenue.&nbsp;
Williams projected second-quarter revenue and EPS of $2.8 million and $(0.07).
Piper Sandler&nbsp;analyst Harsh V. Kumar reiterated an Overweight rating on D-Wave Quantum&nbsp;with a price target of $3.
Kumar is pleased with the strength of traction in D-Wave&#8217;s revenues and technological prowess. The company continues to outpace its competitors in quantum computing, specifically around its annealing solution.&nbsp;&nbsp;
The analyst noted that D-Wave is the only company with a commercial model in the quantum industry. Substantial increases in the company&#8217;s customer portfolio highlighted this once again.&nbsp;
He is also excited about fast annealing technology,&nbsp;which is&nbsp;opening up new avenues for the company&#8217;s growth.
Kumar projected second-quarter revenue and EPS of $2.8 million and $(0.09).
QBTS Price Action:&nbsp;D-Wave Quantum shares traded higher by 1.90% at&nbsp;$1.40 at the last check Tuesday.

Analyst Color

Equities

Reiteration

QBTS

D-Wave Quantum's Fast Anneal To Boost Quantum Processing And Drive Customer Growth, Analysts Say

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock&#39;s price, but are they really important?
Let&#39;s take a look at what these Wall Street heavyweights have to say about CleanSpark (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clsk#NASDAQ">CLSK</a>) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
CleanSpark currently has an average brokerage recommendation&nbsp;of 1.33, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by six brokerage firms. An ABR of 1.33 approximates between Strong Buy and Buy.
Of the six recommendations that derive the current ABR, five are Strong Buy, representing 83.3% of all recommendations.
Brokerage Recommendation Trends for CLSK
<img alt="Broker Rating Breakdown Chart for CLSK" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/CLSK_05142024.png" style="width:100%" title="" /> 
While the ABR calls for buying CleanSpark, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five &quot;Strong Buy&quot; recommendations for every &quot;Strong Sell&quot; recommendation.
In other words, their interests aren&#39;t always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock&#39;s price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock&#39;s near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABR
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company&#39;s changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Is CLSK Worth Investing In?
In terms of earnings estimate revisions for CleanSpark, the Zacks Consensus Estimate for the current year has increased 70% over the past month to $0.52.
Analysts&#39; growing optimism over the company&#39;s earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for CleanSpark.
Therefore, the Buy-equivalent ABR for CleanSpark may serve as a useful guide for investors.
<a href="https://www.zacks.com/stock/news/2273412/is-cleanspark-clsk-a-buy-as-wall-street-analysts-look-optimistic?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2273412">To read this article on Zacks.com click here.</a>

Financial Advisors

Personal Finance

CLSK

Is CleanSpark a Buy as Wall Street Analysts Look Optimistic?

Options

HOOD

Robinhood Markets Option Alert: Jun 21 $19 Calls Sweep (27) near the Ask: 820 @ $1.08 vs 5385 OI; Ref=$17.985

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock&#39;s price, but are they really important?
Let&#39;s take a look at what these Wall Street heavyweights have to say about K12 (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lrn#NYSE">LRN</a>) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
K12 currently has an average brokerage recommendation of 1.40, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by five brokerage firms. An ABR of 1.40 approximates between Strong Buy and Buy.
Of the five recommendations that derive the current ABR, four are Strong Buy, representing 80% of all recommendations.
Brokerage Recommendation Trends for LRN
<img alt="Broker Rating Breakdown Chart for LRN" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/LRN_05142024.png" style="width:100%" title="" /> 
While the ABR calls for buying K12, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five &quot;Strong Buy&quot; recommendations for every &quot;Strong Sell&quot; recommendation.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock&#39;s future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock&#39;s near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABR
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is LRN a Good Investment?
In terms of earnings estimate revisions for K12, the Zacks Consensus Estimate for the current year has increased 5.5% over the past month to $4.55.
Analysts&#39; growing optimism over the company&#39;s earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for K12.
Therefore, the Buy-equivalent ABR for K12 may serve as a useful guide for investors.
<a href="https://www.zacks.com/stock/news/2273411/is-it-worth-investing-in-k12-lrn-based-on-wall-street-s-bullish-views?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2273411">To read this article on Zacks.com click here.</a>

Is It Worth Investing in K12 Based on Wall Street's Bullish Views?

Avadel Pharmaceuticals GAAP EPS of -$0.30 misses by $0.29, revenue of $27.18M beats by $1.28M

Avadel Pharmaceuticals (AVDL – Research Report) received a Buy rating and price target from Craig-Hallum analyst Chase Knickerbocker today. The com...

Avadel Pharmaceuticals (AVDL) Has a New Rating from Craig-Hallum

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Avadel Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/avdl-stock-quote/">AVDL</a>) just reported results for the first quarter of 2024.<ul><li>Avadel Pharmaceuticals reported earnings per share of -30 cents. This was below the analyst estimate for EPS of -21 cents.</li><li>The company reported revenue of $27.18 million.</li><li>This was 1.90% better than the analyst estimate for revenue of $26.67 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/avdl-stock-earnings-avadel-pharmaceuticals-for-q1-of-2024/">AVDL Stock Earnings: Avadel Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AVDL Stock Earnings: Avadel Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024

Avadel Pharmaceuticals plc (AVDL) Q1 2024 Earnings Call Transcript

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Definitive Healthcare Corp (DH – Research Report) ...

Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH) and Avadel Pharmaceuticals (AVDL)

Leerink Partners analyst Marc Goodman reiterated a Buy rating on Avadel Pharmaceuticals (AVDL – Research Report) on May 8 and set a price target of...

Buy Rating Affirmed for Avadel Pharmaceuticals Amidst Strong Growth Potential and Market Expansion

Avadel Pharma gains during hearing over dispute on FDA approval of a sleep disorder drug

Avadel Pharma gains during hearing over dispute on FDA approval of a sleep disorder drug (update)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avadel Pharmaceuticals (AVDL – Research Report), Ake...